Nirmal Bang: Navin Fluorine - Strong Prospects For High Value Verticals

Nirmal Bang: Navin Fluorine - Strong Prospects For High Value Verticals

A lab technician inspects a conical flask containing a mixture inside a research laboratory (Photographer: Stefan Wermuth/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Navin Fluorine International Ltd.’s Q2 FY21 performance was significantly ahead of consensus estimates on all parameters.

Beat on consolidated revenue/Ebitda/profit after tax was to the tune of approximately 16%/~ 30%/~ 38%.

Contract research and manufacturing services business grew by 111% YoY, led by ramp-up of cGMP3 capacity and some bunched-up orders from the previous year.

The management has increased its expected CRAMS quarterly run-rate from ~Rs 500 million to ~Rs 650 million (~30% up) going forward.

Click on the attachment to read the full report:

Nirmal Bang Navin Fluorine International Q2FY21 Result Update-29 October 2020.pdf
Read Document

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Still Not convinced ?  Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
GET REGULAR UPDATES